See more : Loop Media, Inc. (LPTV) Income Statement Analysis – Financial Results
Complete financial analysis of Spyre Therapeutics, Inc. (SYRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Spyre Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Kingstone Mining Holdings Limited (1380.HK) Income Statement Analysis – Financial Results
- OneMeta AI (ONEI) Income Statement Analysis – Financial Results
- Lexston Life Sciences Corp. (LEXT.CN) Income Statement Analysis – Financial Results
- Geodrill Limited (GEO.TO) Income Statement Analysis – Financial Results
- Ecofibre Limited (EOF.AX) Income Statement Analysis – Financial Results
Spyre Therapeutics, Inc. (SYRE)
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 886.00K | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Cost of Revenue | 964.00K | 1.96M | 2.00M | 1.62M | 901.00K | 0.00 | 0.00 | 0.00 | 89.00K | 19.00K |
| Gross Profit | -78.00K | 365.00K | 16.74M | -1.62M | -901.00K | 3.89M | 5.21M | 4.63M | 6.00M | -19.00K |
| Gross Profit Ratio | -8.80% | 15.67% | 89.32% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 98.54% | 0.00% |
| Research & Development | 89.50M | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M | 11.45M | 6.83M |
| General & Administrative | 39.95M | 28.53M | 27.32M | 21.84M | 0.00 | 0.00 | 0.00 | 0.00 | 5.95M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 39.95M | 28.53M | 27.32M | 21.84M | 14.83M | 12.34M | 9.82M | 8.26M | 5.95M | 2.06M |
| Other Expenses | 113.74M | -7.00K | -122.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 243.19M | 87.11M | 84.39M | 81.48M | 79.43M | 49.06M | 32.63M | 26.40M | 17.40M | 8.89M |
| Cost & Expenses | 243.19M | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Interest Income | 6.15M | 837.00K | 111.00K | 593.00K | 2.14M | 1.17M | 482.00K | 244.00K | 22.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 964.00K | 1.96M | 2.00M | 1.62M | 901.00K | 293.00K | 249.00K | 132.00K | 89.00K | 19.00K |
| EBITDA | -127.82M | -83.21M | -63.66M | -79.27M | -77.35M | -45.17M | -27.43M | -21.77M | -11.23M | -10.33M |
| EBITDA Ratio | -14,426.64% | -3,572.95% | -341.92% | 0.00% | 0.00% | -1,161.78% | -526.94% | -470.48% | -184.49% | 0.00% |
| Operating Income | -242.30M | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M | -11.32M | -8.90M |
| Operating Income Ratio | -27,347.97% | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,169.32% | -531.72% | -473.34% | -185.95% | 0.00% |
| Total Other Income/Expenses | -96.51M | 830.00K | -11.00K | 588.00K | 2.08M | 1.12M | 440.00K | 208.00K | 20.00K | -1.44M |
| Income Before Tax | -338.82M | -83.95M | -65.66M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Income Before Tax Ratio | -38,241.08% | -3,604.59% | -350.39% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| Income Tax Expense | -26.00K | -136.00K | 141.00K | -593.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -338.79M | -83.82M | -65.80M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Net Income Ratio | -38,238.15% | -3,598.75% | -351.14% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| EPS | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -53.25 | -45.01 | -55.40 | -25.20 | -18.91 |
| EPS Diluted | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -53.25 | -45.01 | -55.40 | -25.20 | -18.91 |
| Weighted Avg Shares Out | 6.90M | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 547.19K |
| Weighted Avg Shares Out (Dil) | 6.90M | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 547.19K |
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"),...
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , April 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"),...
Spyre Therapeutics Announces $180 Million Private Placement
WALTHAM, Mass. , March 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today...
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , March 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"),...
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the symbol "SYRE" SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing, demonstrated an updated half-life of 22...
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
WALTHAM, Mass. , Feb. 26, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"),...
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
WALTHAM, Mass. , Feb. 8, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"),...
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Spyre Therapeutics (SYRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for...
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
WALTHAM, Mass. , Feb. 5, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"),...
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , Feb. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"),...
Source: https://incomestatements.info
Category: Stock Reports